Tegsedi Helps Preserve Patient Quality of Life in Extension Study

Tegsedi Helps Preserve Patient Quality of Life in Extension Study

304546

Tegsedi Helps Preserve Patient Quality of Life in Extension Study

Long-term treatment with Tegsedi (inotersen) helps preserve quality of life in people with familial amyloid polyneuropathy (FAP) for up to three years, according to data from the Phase 3 NEURO-TTR trial and its extension study. While patients initially assigned to a placebo stopped experiencing declines in quality of life after switching to Tegsedi in the extension study, they did not attain the same quality of life levels as those who were initially assigned to and…

You must be logged in to read/download the full post.